INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
| Mar2021 | ₹3.92 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | 3.96 | |
| Mar2021 | ₹3.92 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹251.4 Cr | -2.3% | -3% | -63.2% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹13,014.5 Cr | -1.4% | 1.9% | -21.2% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹5,019.4 Cr | 1.2% | -8.8% | 2.3% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,008.4 Cr | 2.2% | 5% | -23.2% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,058.6 Cr | 4.1% | -13.9% | -39.7% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹496.6 Cr | 3.4% | 9.1% | 27.9% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -2.3% |
-3% |
-63.2% |
| SENSEX | 0.1% |
0.9% |
4.5% |
You may also like the below Video Courses